Retirement Systems of Alabama Sells 5,613 Shares of Halozyme Therapeutics, Inc. $HALO

Retirement Systems of Alabama trimmed its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 1.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 346,841 shares of the biopharmaceutical company’s stock after selling 5,613 shares during the quarter. Retirement Systems of Alabama’s holdings in Halozyme Therapeutics were worth $38,291,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in HALO. Horizon Investment Services LLC purchased a new stake in shares of Halozyme Therapeutics during the second quarter worth about $2,254,000. WINTON GROUP Ltd raised its position in Halozyme Therapeutics by 704.6% during the 2nd quarter. WINTON GROUP Ltd now owns 60,348 shares of the biopharmaceutical company’s stock valued at $4,723,000 after purchasing an additional 52,848 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in Halozyme Therapeutics during the 2nd quarter valued at approximately $1,025,000. Great Lakes Advisors LLC purchased a new stake in Halozyme Therapeutics in the 2nd quarter worth approximately $2,821,000. Finally, Chase Investment Counsel Corp purchased a new stake in Halozyme Therapeutics in the 2nd quarter worth approximately $2,035,000. Institutional investors own 97.79% of the company’s stock.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Matthew L. Posard sold 18,996 shares of Halozyme Therapeutics stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $107.74, for a total value of $2,046,629.04. Following the completion of the sale, the director owned 58,839 shares of the company’s stock, valued at approximately $6,339,313.86. This trade represents a 24.41% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction on Wednesday, September 9th. The stock was sold at an average price of $107.43, for a total value of $2,148,600.00. Following the completion of the transaction, the chief executive officer owned 767,780 shares of the company’s stock, valued at $82,482,605.40. This represents a 2.54% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 124,226 shares of company stock worth $13,370,893 over the last ninety days. 2.50% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

HALO has been the topic of a number of recent analyst reports. Weiss Ratings upgraded Halozyme Therapeutics from a “buy (b)” rating to a “buy (b+)” rating in a research report on Monday. Benchmark reissued a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, July 21st. Citigroup reissued a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Friday, August 7th. Stifel Nicolaus set a $130.00 price objective on shares of Halozyme Therapeutics in a report on Friday, October 16th. Finally, JPMorgan Chase & Co. raised their target price on shares of Halozyme Therapeutics from $78.00 to $79.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 3rd. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $108.18.

Halozyme Therapeutics Stock Performance

Shares of HALO opened at $102.98 on Wednesday. Halozyme Therapeutics, Inc. has a 52 week low of $61.22 and a 52 week high of $134.00. The stock has a market cap of $11.74 billion, a P/E ratio of 26.20, a P/E/G ratio of 0.39 and a beta of 0.92. The business’s 50 day moving average price is $115.07 and its 200-day moving average price is $85.05. The company has a quick ratio of 3.60, a current ratio of 3.88 and a debt-to-equity ratio of 13.50.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported $2.39 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.30 by $0.09. The company had revenue of $492.97 million for the quarter, compared to analysts’ expectations of $491.63 million. Halozyme Therapeutics had a net margin of 26.93% and a return on equity of 751.81%. Halozyme Therapeutics’s revenue was up 39.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.72 EPS. Equities research analysts anticipate that Halozyme Therapeutics, Inc. will post 8.34 earnings per share for the current fiscal year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing drug-delivery technologies and medicines. Its ENHANZE platform uses a recombinant human hyaluronidase enzyme, rHuPH20, to temporarily modify tissue under the skin and help enable the subcutaneous administration of certain biologic medicines that might otherwise require intravenous infusion. Halozyme licenses ENHANZE to pharmaceutical and biotechnology partners, which use the technology in their own products. The company also markets Hylenex recombinant, a hyaluronidase product used to facilitate the dispersion and absorption of other injected medicines and fluids.